ErbB receptors: directing key signaling networks throughout life.
暂无分享,去创建一个
[1] J. Biegel,et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. , 1995, Cancer research.
[2] M. Sliwkowski,et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). , 1999, Seminars in oncology.
[3] D. Wilkinson,et al. Molecular control of neural crest formation, migration and differentiation. , 2000, Current opinion in cell biology.
[4] Z. Werb,et al. The metalloprotease Kuzbanian (ADAM10) mediates the transactivation of EGF receptor by G protein–coupled receptors , 2002, The Journal of cell biology.
[5] D. Yee,et al. Phosphorylation and nuclear exclusion of the forkhead transcription factor FKHR after epidermal growth factor treatment in human breast cancer cells , 2000, Oncogene.
[6] W. Gullick,et al. Identification of c‐erbB‐3 binding sites for phosphatidylinositol 3′‐kinase and SHC using an EGF receptor/c‐erbB‐3 chimera. , 1994, The EMBO journal.
[7] L. Norton,et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. , 1998, Cancer research.
[8] Y. Sagara,et al. Co‐expression of epidermal growth factor receptor and transforming growth factor‐α predicts worse prognosis in breast‐cancer patients , 2000, International journal of cancer.
[9] R. Breathnach,et al. Epidermal growth factor stimulates transcription of the c-jun proto-oncogene in rat fibroblasts , 1988, Nature.
[10] G. Stenman,et al. Expression of the ERBB2 protein in benign and malignant salivary gland tumors , 1991, Genes, chromosomes & cancer.
[11] M. Sliwkowski,et al. Identification of a Region within the ErbB2/HER2 Intracellular Domain That Is Necessary for Ligand-independent Association* , 2002, The Journal of Biological Chemistry.
[12] J. Massagué,et al. Membrane-anchored growth factors. , 1993, Annual review of biochemistry.
[13] A. Ullrich,et al. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor , 1989, Molecular and cellular biology.
[14] L. Cantley,et al. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[15] Y. Taketani,et al. Constitutive Tyrosine Phosphorylation of ErbB-2 via Jak2 by Autocrine Secretion of Prolactin in Human Breast Cancer* , 2000, The Journal of Biological Chemistry.
[16] John Mendelsohn,et al. The EGF receptor family as targets for cancer therapy , 2000, Oncogene.
[17] D. O’Rourke,et al. Domain-specific Interactions between the p185 neu and Epidermal Growth Factor Receptor Kinases Determine Differential Signaling Outcomes* , 1999, The Journal of Biological Chemistry.
[18] C. Dinney,et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[19] C. Howe,et al. Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: clinicopathological correlates. , 2002, Cancer research.
[20] G. Carpenter,et al. Selective Cleavage of the Heregulin Receptor ErbB-4 by Protein Kinase C Activation* , 1996, The Journal of Biological Chemistry.
[21] B. Wörmann,et al. Trastuzumab and breast cancer. , 2001, The New England journal of medicine.
[22] H. Scher,et al. Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. , 1996, Cancer research.
[23] A. Ullrich,et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF , 1999, Nature.
[24] C. Benz,et al. Inhibition of transcription factor binding to the HER2 promoter by triplex-forming oligodeoxyribonucleotides. , 1994, Gene.
[25] M. Kraus,et al. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. , 1995, Oncogene.
[26] J. Ross,et al. The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy , 1998, Stem cells.
[27] K. Sugimachi,et al. Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. , 1991, European journal of cancer.
[28] Rüdiger Klein,et al. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor , 1995, Nature.
[29] M. Klagsbrun,et al. Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase , 1999, Oncogene.
[30] H. Juhl,et al. HER-2/neu Is Rate-limiting for Ovarian Cancer Growth , 1997, The Journal of Biological Chemistry.
[31] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[32] Monilola A. Olayioye,et al. ErbB-1 and ErbB-2 Acquire Distinct Signaling Properties Dependent upon Their Dimerization Partner , 1998, Molecular and Cellular Biology.
[33] J. Hassell,et al. The PEA3 Ets transcription factor is a downstream target of the HER2/Neu receptor tyrosine kinase , 1998, Oncogene.
[34] Y. Yarden,et al. Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.
[35] D. Riethmacher,et al. Severe neuropathies in mice with targeted mutations in the ErbB3 receptor , 1997, Nature.
[36] N. Hynes,et al. The ErbB receptors and their role in cancer progression. , 2003, Experimental cell research.
[37] Debajit K. Biswas,et al. Epidermal growth factor-induced nuclear factor κB activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells , 2000 .
[38] N. Hynes,et al. ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.
[39] N. Bander,et al. Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[40] J. Baselga,et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] E. Rowinsky,et al. The ErbB receptor family: a therapeutic target for cancer. , 2002, Trends in molecular medicine.
[42] N. Rosen,et al. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. , 2001, Cancer research.
[43] N. Rosen,et al. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2 , 2002, Oncogene.
[44] Edouard C. Nice,et al. Crystal Structure of a Truncated Epidermal Growth Factor Receptor Extracellular Domain Bound to Transforming Growth Factor α , 2002, Cell.
[45] A. Pardee,et al. Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[46] D. W. Fry. Mechanism of action of erbB tyrosine kinase inhibitors. , 2003, Experimental cell research.
[47] N. Lemoine,et al. Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer. , 1991, British Journal of Cancer.
[48] R. Day,et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. , 1998, Journal of the National Cancer Institute.
[49] D. Riethmacher,et al. The ErbB2 and ErbB3 receptors and their ligand, neuregulin-1, are essential for development of the sympathetic nervous system. , 1998, Genes & development.
[50] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[51] W. Gullick,et al. c‐erbB‐2 oncogene product staining in gastric adenocarcinoma. An immunohistochemical study , 1989, The Journal of pathology.
[52] B. Shilo,et al. Keren, a new ligand of the Drosophila epidermal growth factor receptor, undergoes two modes of cleavage , 2002, The EMBO journal.
[53] M. Rudnicki,et al. ErbB2 Is Required for Muscle Spindle and Myoblast Cell Survival , 2002, Molecular and Cellular Biology.
[54] M. Kraus,et al. Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members , 1994, Molecular and cellular biology.
[55] R. Nicholson,et al. EGFR and cancer prognosis. , 2001, European journal of cancer.
[56] Hiroshi Asanuma,et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy , 2002, Nature Medicine.
[57] A. Kinniburgh,et al. Induction of c-fos and c-myc proto-oncogene expression by epidermal growth factor and transforming growth factor alpha is calcium-independent. , 1989, The Journal of biological chemistry.
[58] C. Barbas,et al. Positive and negative regulation of endogenous genes by designed transcription factors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[59] P. Harari,et al. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). , 2002, Cancer research.
[60] Edward S. Kim,et al. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer , 2001, Seminars in oncology.
[61] E. Wilkinson. Surprise phase III failure for ZD1839. , 2002, The Lancet. Oncology.
[62] E. Dmitrovsky,et al. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[63] Y. Yonekawa,et al. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. , 1996, Brain pathology.
[64] Monilola A. Olayioye,et al. ErbB Receptor-induced Activation of Stat Transcription Factors Is Mediated by Src Tyrosine Kinases* , 1999, The Journal of Biological Chemistry.
[65] N. Normanno,et al. Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.
[66] C. Hudis,et al. Cardiac dysfunction in the trastuzumab clinical trials experience. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] C. Birchmeier,et al. Multiple essential functions of neuregulin in development , 1995, Nature.
[68] M. Yaffe. Phosphotyrosine-binding domains in signal transduction , 2002, Nature Reviews Molecular Cell Biology.
[69] N. Robert,et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] N. Copeland,et al. The mouse waved-2 phenotype results from a point mutation in the EGF receptor tyrosine kinase. , 1994, Genes & development.
[71] A dual role of erbB2 in myelination and in expansion of the schwann cell precursor pool. , 2000 .
[72] W. Muller,et al. The Catalytic Activity of the ErbB-2 Receptor Tyrosine Kinase Is Essential for Embryonic Development , 2002, Molecular and Cellular Biology.
[73] Susumu Minamisawa,et al. ErbB2 is essential in the prevention of dilated cardiomyopathy , 2002, Nature Medicine.
[74] C. James,et al. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[75] C. Dinney,et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[76] A. Ullrich,et al. Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure. , 1995, The EMBO journal.
[77] Kuo-Fen Lee,et al. Rescue of the Cardiac Defect in ErbB2 Mutant Mice Reveals Essential Roles of ErbB2 in Peripheral Nervous System Development , 1999, Neuron.
[78] Kuo-Fen Lee,et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development , 1995, Nature.
[79] N. Goldstein,et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[80] A. Ullrich,et al. Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission , 2001, Oncogene.
[81] N. Rosen,et al. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. , 1995, The Journal of clinical investigation.
[82] G. Carpenter,et al. All ErbB Receptors Other Than the Epidermal Growth Factor Receptor Are Endocytosis Impaired (*) , 1996, The Journal of Biological Chemistry.
[83] R. Day,et al. Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival , 1998 .
[84] D. Stern,et al. Specificity within the EGF family/ErbB receptor family signaling network , 1998, BioEssays : news and reviews in molecular, cellular and developmental biology.
[85] Monilola A. Olayioye,et al. The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.
[86] Michael Kofler,et al. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. , 2003, Molecular cell.
[87] Y. Yarden,et al. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[88] L. Cantley,et al. Ligand Discrimination in Signaling through an ErbB4 Receptor Homodimer* , 2000, The Journal of Biological Chemistry.
[89] K. Herrup,et al. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. , 1995, Science.
[90] Hyun-soo Cho,et al. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. , 2003, Molecular cell.
[91] E. Wagner,et al. A strain‐independent postnatal neurodegeneration in mice lacking the EGF receptor , 1998, The EMBO journal.
[92] D. Seals,et al. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. , 2003, Genes & development.
[93] Z. Kam,et al. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. , 1998, Genes & development.
[94] M. Rubin,et al. Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. , 1996, Oncogene.
[95] 平田 晃. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase , 2004 .
[96] R. Derynck,et al. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor , 1995, Nature.
[97] S. Parsons,et al. Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[98] P. Carroll,et al. Heterogeneity of erbB-2 gene amplification in bladder cancer. , 1993, Cancer research.
[99] Kohjiro Ueki,et al. Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone , 1997, Nature.
[100] J. Ross,et al. The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy , 1998, The oncologist.
[101] P. Sternberg,et al. C. elegans Vulval Development as a Model System to Study the Cancer Biology of EGFR Signaling , 2004, Cancer and Metastasis Reviews.
[102] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[103] M. Lemmon,et al. Extracellular domains drive homo‐ but not hetero‐dimerization of erbB receptors , 2000, The EMBO journal.
[104] C. Arteaga,et al. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. , 2002, Cancer research.
[105] L. Cantley,et al. p120 Is a Cytosolic Adapter Protein That Associates with Phosphoinositide 3-Kinase in Response to Epidermal Growth Factor in PC12 and Other Cells (*) , 1996, The Journal of Biological Chemistry.
[106] N. Hynes,et al. The biology of erbB-2/neu/HER-2 and its role in cancer. , 1994, Biochimica et biophysica acta.
[107] M. Hung,et al. HER-2/neu Blocks Tumor Necrosis Factor-induced Apoptosis via the Akt/NF-κB Pathway* , 2000, The Journal of Biological Chemistry.
[108] M. Freeman,et al. A family of Rhomboid intramembrane proteases activates all Drosophila membrane‐tethered EGF ligands , 2002, The EMBO journal.
[109] J. Schlessinger. Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.
[110] D. Stern,et al. ErbBs in mammary development. , 2003, Experimental cell research.
[111] L. Presta,et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.
[112] P. Sismondi,et al. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. , 1996, British Journal of Cancer.
[113] G. Tortora,et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[114] B. Geiger,et al. Alternative Intracellular Routing of ErbB Receptors May Determine Signaling Potency* , 1998, The Journal of Biological Chemistry.
[115] R. Neve,et al. Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells , 2000, Oncogene.
[116] Carmen Birchmeier,et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[117] Y. Yarden,et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor , 1996, Molecular and cellular biology.
[118] G. Carpenter. EGF Receptor Transactivation Mediated by the Proteolytic Production of EGF-like Agonists , 2000, Science's STKE.
[119] J. Grandis,et al. Quantitative immunohistochemical analysis of transforming growth factor‐α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck , 1996, Cancer.
[120] F. Shepherd,et al. Co-expression of epidermal growth factor receptor and transforming growth factor-alpha is independent of ras mutations in lung adenocarcinoma. , 2000, Lung cancer.
[121] F. Maurer,et al. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[122] C. Arteaga,et al. Tyrosine kinase inhibitors—ZD1839 (Iressa) , 2001, Current opinion in oncology.
[123] J G Klijn,et al. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. , 1992, Endocrine reviews.
[124] N. Hynes,et al. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling , 1995, Molecular and cellular biology.
[125] John M. Daly,et al. ErbB2 Potentiates Breast Tumor Proliferation through Modulation of p27Kip1-Cdk2 Complex Formation: Receptor Overexpression Does Not Determine Growth Dependency , 2000, Molecular and Cellular Biology.
[126] C. Macleod,et al. Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[127] B. Shilo,et al. A thousand and one roles for the Drosophila EGF receptor. , 1997, Trends in genetics : TIG.
[128] A. Ullrich,et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences , 1984, Nature.
[129] A. Ullrich,et al. Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal transactivation. , 2002, Cancer research.
[130] N. Hynes,et al. Wnt1 and Wnt5a induce cyclin D1 expression through ErbB1 transactivation in HC11 mammary epithelial cells (EMBO reports, February 2003) (Correction) , 2003, EMBO reports.
[131] Brian Higgins,et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. , 2002, Cancer cell.
[132] E. Nice,et al. Mice with a null mutation of the TGFα gene have abnormal skin architecture, wavy hair, and curly whiskers and often develop corneal inflammation , 1993, Cell.
[133] D. W. Green,et al. HER2/neu antisense targeting of human breast carcinoma , 2000, Oncogene.
[134] A. Lenferink,et al. Differential endocytic routing of homo‐ and hetero‐dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers , 1998, The EMBO journal.
[135] H. Poulsen,et al. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[136] P. Traxler,et al. Tyrosine kinases as targets in cancer therapy – successes and failures , 2003, Expert opinion on therapeutic targets.
[137] P. Caroni,et al. Peripheral nervous system defects in erbB2 mutants following genetic rescue of heart development. , 1999, Genes & development.
[138] M. Maa,et al. c-Src-mediated Phosphorylation of the Epidermal Growth Factor Receptor on Tyr845 and Tyr1101 Is Associated with Modulation of Receptor Function* , 1999, The Journal of Biological Chemistry.
[139] M. Kris,et al. Trastuzumab in the treatment of non-small cell lung cancer. , 2002, Seminars in oncology.
[140] M. C. Hu,et al. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. , 2000, The Journal of biological chemistry.
[141] Hyun-soo Cho,et al. Structure of the Extracellular Region of HER3 Reveals an Interdomain Tether , 2002, Science.
[142] S. Klewer,et al. Heart-valve mesenchyme formation is dependent on hyaluronan-augmented activation of ErbB2–ErbB3 receptors , 2002, Nature Medicine.
[143] C. Benz,et al. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[144] D. Sawyer,et al. Modulation of Anthracycline-Induced Myofibrillar Disarray in Rat Ventricular Myocytes by Neuregulin-1&bgr; and Anti-erbB2: Potential Mechanism for Trastuzumab-Induced Cardiotoxicity , 2002, Circulation.
[145] Y. Yarden,et al. Neu Differentiation Factor Stimulates Phosphorylation and Activation of the Sp1 Transcription Factor , 1999, Molecular and Cellular Biology.
[146] A. M. Stanley,et al. Structure of the extracellular region of HER 2 alone and in complex with the Herceptin Fab , 2022 .
[147] I. Fariñas,et al. Erbb2 regulates neuromuscular synapse formation and is essential for muscle spindle development , 2003, Development.
[148] Antony W Burgess,et al. Epidermal growth factor receptor: mechanisms of activation and signalling. , 2003, Experimental cell research.
[149] A Ciechanover,et al. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. , 1999, Molecular cell.
[150] A. Ullrich,et al. Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells , 1987, Cell.
[151] Jae-Hoon Kim,et al. Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains , 2002, Cell.